TTF-1 negativity as a biomarker of outcomes to immunotherapy, chemoimmunotherapy, and KRAS G12C inhibitors in lung adenocarcinoma Meeting Abstract

  

Authors:	Di Federico, A.; Hong, L.; Elkrief, A.; Thummalapalli, R.; Cooper, A. J.; Shaverdian, N.; Ricciuti, B.; Alessi, J. V. M.; De Giglio, A.; Pecci, F.; Lamberti, G.; Gandhi, M. M.; Sholl, L. M.; Nishino, M.; Ardizzoni, A.; Heist, R. S.; Arbour, K. C.; Schoenfeld, A. J.; Vokes, N. I.; Awad, M. M.
Abstract Title:	TTF-1 negativity as a biomarker of outcomes to immunotherapy, chemoimmunotherapy, and KRAS G12C inhibitors in lung adenocarcinoma
Meeting Title:	2024 ASCO Annual Meeting
Journal Title:	Journal of Clinical Oncology
Volume:	42
Issue:	16 Suppl.
Meeting Dates:	2024 May 31-Jun 4
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2024-06-01
Language:	English
ACCESSION:	WOS:001275557402103
PROVIDER:	wos
DOI:	10.1200/JCO.2024.42.16_suppl.8608
Notes:	Meeting Abstract: 8608 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/218789